Aro Biotherapeutics Secures $41.5M Series B Financing
11/28/23, 2:01 PM
Location
philadelphiaMoney raised
$41.5 million
Industry
biotechnology
Round Type
series b
Investors
Christopher Picariello, President, Jjdc, Bvf Partners, L.P., Healthcap, Northpond Ventures, Jjdc, Inc., Johnson & Johnson Innovation, Cowen Healthcare Investments
Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced it has secured $41.5M in a Series B funding round. The round was led by Cowen Healthcare Investments, with participation from existing investors from Aro’s Series A financing round in 2020, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Northpond Ventures, Healthcap and BVF Partners, L.P. In conjunction with the financing, Christopher Picariello, President, JJDC, has joined Aro’s Board of Directors.
Company Info
Location
3675 market street, suite 200
philadelphia, pennsylvania, united states
Additional Info
Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.